Abstract
CpG are powerful drugs activating the innate immune system. In this study, the ability of their intramammary administration in impeding the devastating progression of carcinogenesis in all the mammary glands of female BALB/c mice transgenic for the rat neu transforming oncogene was assessed. Starting when in situ carcinomas were scattered over all their mammary glands (week 10), mice received CpG injections in the stroma of the fourth left gland. Local neoplastic progression was inhibited by six monthly administrations. CpG not only delayed the onset of carcinomas in the injected gland, but also hampered their progression. Extended latency was observed for tumors in glands both close to and far from the injection site. When the experiment ended (week 45), no tumors were palpable in 67% of the injected glands and a markedly impaired tumor growth was evident in the others. An impressive local infiltrate of CD11b+ cells with the morphologic features of macrophages, plasma cells, B220+ B cells, and CD4+ and CD8+ T cells was quickly recruited to the CpG-treated glands. High quantities of IFN-γ producing cells were only present in the ipsilateral axillary draining lymph nodes of the treated glands. Enhanced natural killer (NK) lytic activity was also detected in the spleens. Inhibition of progression was weaker when only four injections were given, and abolished by in vivo depletion of NK cells. CpG monotherapy is thus effective in an aggressive model of autochthonous cancer. The results strongly support the administration of CpG as a local monotherapy of multiple invasive microscopic lesions.
Current Cancer Drug Targets
Title: Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice
Volume: 8 Issue: 3
Author(s): Cristina Mastini, Pablo D. Becker, Manuela Iezzi, Claudia Curcio, Piero Musiani, Guido Forni, Federica Cavallo and Carlos A. Guzman
Affiliation:
Keywords: Her-2/neu, CpG, NK cells
Abstract: CpG are powerful drugs activating the innate immune system. In this study, the ability of their intramammary administration in impeding the devastating progression of carcinogenesis in all the mammary glands of female BALB/c mice transgenic for the rat neu transforming oncogene was assessed. Starting when in situ carcinomas were scattered over all their mammary glands (week 10), mice received CpG injections in the stroma of the fourth left gland. Local neoplastic progression was inhibited by six monthly administrations. CpG not only delayed the onset of carcinomas in the injected gland, but also hampered their progression. Extended latency was observed for tumors in glands both close to and far from the injection site. When the experiment ended (week 45), no tumors were palpable in 67% of the injected glands and a markedly impaired tumor growth was evident in the others. An impressive local infiltrate of CD11b+ cells with the morphologic features of macrophages, plasma cells, B220+ B cells, and CD4+ and CD8+ T cells was quickly recruited to the CpG-treated glands. High quantities of IFN-γ producing cells were only present in the ipsilateral axillary draining lymph nodes of the treated glands. Enhanced natural killer (NK) lytic activity was also detected in the spleens. Inhibition of progression was weaker when only four injections were given, and abolished by in vivo depletion of NK cells. CpG monotherapy is thus effective in an aggressive model of autochthonous cancer. The results strongly support the administration of CpG as a local monotherapy of multiple invasive microscopic lesions.
Export Options
About this article
Cite this article as:
Mastini Cristina, Becker D. Pablo, Iezzi Manuela, Curcio Claudia, Musiani Piero, Forni Guido, Cavallo Federica and Guzman A. Carlos, Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice, Current Cancer Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/156800908784293604
DOI https://dx.doi.org/10.2174/156800908784293604 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiogenesis New Targets for the Development of Anticancer Chemotherapies
Current Pharmaceutical Design Development of Thiazole-5-carboxylate Derivatives as Selective Inhibitors of Monoacylglycerol Lipase as Target in Cancer
Mini-Reviews in Medicinal Chemistry TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Anti-Proliferative Role of the Tyrosine Kinase Inhibitors TKI-258 on Oral Squamous Cell Carcinoma In Vitro
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Protein Kinase Inhibitors: Current Strategies and Future Prospects (Executive Guest Editor: Julio Caballero)]
Current Pharmaceutical Design Molecular Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Hemodialysis Patients
Current Signal Transduction Therapy The Plant Resources, Structure Characteristics, Biological Activities and Synthesis of Pyranoflavonoids
Current Medicinal Chemistry Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery Variability of Biological Activities of Limonoids Derived from Plant Sources
Mini-Reviews in Organic Chemistry Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design The Therapeutic Potential of miR-7 in Cancers
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Treatment of Cancer in the Elderly)
Anti-Cancer Agents in Medicinal Chemistry Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design The Association of Collagenase with Human Diseases and its Therapeutic Potential in Overcoming them
Current Biotechnology Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Wheel of Fortune – Cyclic Peptides Hit the Mimetic Jackpot: Current Syntheses, Uses and Roles for Cyclic Peptide Mimetics
Current Chemical Biology A Review on Phytopharmaceuticals having Concomitant Experimental Anti-diabetic and Anti-cancer Effects as Potential Sources for Targeted Therapies Against Insulin-mediated Breast Cancer Cell Invasion and Migration
Current Cancer Therapy Reviews A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets